Compare Novo Nordisk A/S (NVO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sanofi SA — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Novo Nordisk A/S is far larger — about 2.1× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| NVO | SNY | |
|---|---|---|
Market Cap | $220.53B | $104.83B |
Sector | Health | Health |
52-Week High | $71.70 | $52.34 |
52-Week Low | $35.29 | $41.33 |
Enterprise Value | $239.49B | $121.32B |
Dividend Yield | 3.63% | 5.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
